Answers are grounded in this paper and cite their sources.
Introduction: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disorder affecting the nasal and paranasal sinus mucosa for more than 12 weeks, with a significant global health impact. The conventional phenotypic classification into CRS with and without nasal polyps is insufficient to capture its immunological complexity. Recent research supports a molecular endotyping approach, each associated with distinct immunological markers and treatment responses. Objective: To systematically evaluate the relationship between molecular endotypes of CRS and their respective responses to medical and surgical treatment. Methods: A systematic review of the literature was conducted, and 10 studies were included in the qualitative synthesis. These studies were assessed for risk of bias (RoB) using the RoB 2 tool for randomized trials and the Newcastle–Ottawa Scale for observational studies. Results: Type 2 inflammation – characterized by elevated Interleukin (IL)-4, IL-5, IL-13, and eosinophilia – showed a superior response to corticosteroids and biologics such as dupilumab and mepolizumab. In contrast, Type 1 and Type 3 endotypes (linked to Th1/Th17 cytokines and neutrophilia) responded better to antibiotics and macrolides but poorly to corticosteroids and anti-Th2 therapies. The most significant numerical outcome was a 76% reduction in the need for systemic corticosteroids or surgery in Type 2 CRS patients treated with dupilumab. Discussion: The review confirms that treatment efficacy in CRS is strongly influenced by underlying molecular endotypes. Type 2 inflammation is a robust predictor of good response to corticosteroids and biologics. Conversely, Types 1 and 3 require alternative treatments, and future research should focus on targeted therapies for these less responsive endotypes.
No takes yet. Share an insight, caveat, or question.
Álzate et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: